Page 48 - சர்வதேச கூட்டமைப்பு ஆஃப் மருந்து உற்பத்தியாளர்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Henry Skinner has been appointed as the first CEO of the AMR Action Fund The AMR Action Fund is aiming to strengthen and accelerate antibiotic development Henry Skinner (pictured above) has been appointed the first chief executive officer of the AMR Action Fund, an initiative aiming to strengthen and accelerate antibiotic development. Skinner joins the AMR Action Fund with extensive biomedical and investment funding experience, having spent decades in the biomedical research, venture and the pharmaceutical industries. Most recently, he served as the senior vice president of venture at Tekla Capital Management. Prior to that, he has served as vice president and deputy head and managing director of the Novartis Venture Fund, as well as executive director, head strategic alliances at Novartis Institutes for Biomedical Research.

Henry skinnerMartin bottNovartis institutes for biomedical researchSelectx pharmaceuticalsAction fundWorld health organizationInternational federation of pharmaceutical manufacturersNovartis venture fundEuropean investment bankNeogenesis pharmaceuticalsTekla capitalNovartis institutesInternational federationPharmaceutical manufacturersஹென்றி ஸ்கின்னர்மார்டின் பாட்டில்